Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes.

Dawwas, Ghadeer K; Cuker, Adam; Connors, Jean Marie; Barnes, Geoffrey D

Dawwas, Ghadeer K; Cuker, Adam; Connors, Jean Marie; Barnes, Geoffrey D.

Afiliação

Dawwas GK; Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Cuker A; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Connors JM; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Barnes GD; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Am J Hematol ; 97(5): E173-E176, 2022 05.

Article em En | MEDLINE | ID: mdl-35147235

Assuntos

Rivaroxabana; Acidente Vascular Cerebral; Anticoagulantes/efeitos adversos; Dabigatrana; Atenção à Saúde; Humanos; Pirazóis/efeitos adversos; Piridonas/efeitos adversos; Estudos Retrospectivos; Rivaroxabana/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acidente Vascular Cerebral / Rivaroxabana Tipo de estudo: Evaluation_studies / Observational_studies Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google